Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !
Dallah Healthcare Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
Dallah Healthcare wird ein jährliches Gewinn- und Umsatzwachstum von 16% bzw. 9.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 14.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 16.6% betragen.
Wichtige Informationen
16.0%
Wachstumsrate der Gewinne
14.7%
EPS-Wachstumsrate
| Healthcare Gewinnwachstum | 15.0% |
| Wachstumsrate der Einnahmen | 9.9% |
| Zukünftige Eigenkapitalrendite | 16.6% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 20 May 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Investors Will Want Dallah Healthcare's (TADAWUL:4004) Growth In ROCE To Persist
May 30
We Ran A Stock Scan For Earnings Growth And Dallah Healthcare (TADAWUL:4004) Passed With Ease
Apr 16What You Can Learn From Dallah Healthcare Company's (TADAWUL:4004) P/E
Mar 18Returns On Capital At Dallah Healthcare (TADAWUL:4004) Have Hit The Brakes
Feb 25Dallah Healthcare (TADAWUL:4004) Has More To Do To Multiply In Value Going Forward
Oct 30Dallah Healthcare (TADAWUL:4004) Is Reinvesting At Lower Rates Of Return
Jul 26Returns On Capital Signal Tricky Times Ahead For Dallah Healthcare (TADAWUL:4004)
Apr 17Is Now The Time To Put Dallah Healthcare (TADAWUL:4004) On Your Watchlist?
Feb 06Dallah Healthcare (TADAWUL:4004) Will Want To Turn Around Its Return Trends
Dec 05We Ran A Stock Scan For Earnings Growth And Dallah Healthcare (TADAWUL:4004) Passed With Ease
Nov 01Calculating The Intrinsic Value Of Dallah Healthcare Company (TADAWUL:4004)
Aug 28Dallah Healthcare (TADAWUL:4004) Has Some Way To Go To Become A Multi-Bagger
Aug 12Here's Why We Think Dallah Healthcare (TADAWUL:4004) Is Well Worth Watching
Jul 28Industry Analysts Just Upgraded Their Dallah Healthcare Company (TADAWUL:4004) Revenue Forecasts By 10%
May 26Calculating The Fair Value Of Dallah Healthcare Company (TADAWUL:4004)
May 20Here's Why We Think Dallah Healthcare (TADAWUL:4004) Is Well Worth Watching
Apr 16Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively
Feb 03Is Now The Time To Put Dallah Healthcare (TADAWUL:4004) On Your Watchlist?
Jan 10Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively
Oct 19Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively
Jul 09Forecast: Analysts Think Dallah Healthcare Company's (TADAWUL:4004) Business Prospects Have Improved Drastically
Jun 16Broker Revenue Forecasts For Dallah Healthcare Company (TADAWUL:4004) Are Surging Higher
May 02What Kind Of Shareholders Hold The Majority In Dallah Healthcare Company's (TADAWUL:4004) Shares?
Mar 17Has Dallah Healthcare (TADAWUL:4004) Got What It Takes To Become A Multi-Bagger?
Mar 02Dallah Healthcare (TADAWUL:4004) Shareholders Booked A 45% Gain In The Last Year
Feb 15Should You Buy Dallah Healthcare Company (TADAWUL:4004) For Its Dividend?
Feb 01Are Dallah Healthcare's (TADAWUL:4004) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 05
Dallah Healthcare Company's (TADAWUL:4004) Intrinsic Value Is Potentially 26% Below Its Share Price
Dec 22Will Dallah Healthcare (TADAWUL:4004) Multiply In Value Going Forward?
Nov 20Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 3,813 | 588 | 551 | 769 | 6 |
| 12/31/2025 | 3,550 | 505 | 346 | 697 | 8 |
| 12/31/2024 | 3,240 | 445 | 285 | 614 | 2 |
| 3/31/2024 | 3,010 | 385 | 415 | 724 | N/A |
| 12/31/2023 | 2,943 | 360 | 329 | 626 | N/A |
| 9/30/2023 | 2,831 | 325 | 348 | 562 | N/A |
| 6/30/2023 | 2,682 | 270 | 369 | 549 | N/A |
| 3/31/2023 | 2,595 | 286 | 333 | 519 | N/A |
| 12/31/2022 | 2,488 | 274 | 267 | 442 | N/A |
| 9/30/2022 | 2,370 | 305 | 214 | 367 | N/A |
| 6/30/2022 | 2,313 | 311 | 122 | 260 | N/A |
| 3/31/2022 | 2,220 | 289 | 166 | 290 | N/A |
| 12/31/2021 | 2,105 | 259 | 246 | 362 | N/A |
| 9/30/2021 | 1,935 | 202 | 178 | 305 | N/A |
| 6/30/2021 | 1,742 | 206 | 240 | 363 | N/A |
| 3/31/2021 | 1,498 | 165 | 110 | 215 | N/A |
| 12/31/2020 | 1,318 | 132 | 54 | 183 | N/A |
| 9/30/2020 | 1,257 | 150 | 82 | 211 | N/A |
| 6/30/2020 | 1,207 | 123 | 35 | 198 | N/A |
| 3/31/2020 | 1,246 | 131 | 33 | 244 | N/A |
| 12/31/2019 | 1,252 | 147 | 106 | 307 | N/A |
| 9/30/2019 | 1,227 | 110 | 88 | 290 | N/A |
| 6/30/2019 | 1,206 | 115 | 43 | 264 | N/A |
| 3/31/2019 | 1,193 | 119 | 5 | 255 | N/A |
| 12/31/2018 | 1,181 | 142 | -51 | 204 | N/A |
| 9/30/2018 | 1,189 | 172 | -158 | 184 | N/A |
| 6/30/2018 | 1,203 | 217 | -131 | 253 | N/A |
| 3/31/2018 | 1,218 | 268 | -98 | 297 | N/A |
| 12/31/2017 | 1,212 | 295 | N/A | 353 | N/A |
| 9/30/2017 | 1,202 | 284 | N/A | 457 | N/A |
| 6/30/2017 | 1,180 | 268 | N/A | 387 | N/A |
| 3/31/2017 | 1,181 | 252 | N/A | 382 | N/A |
| 12/31/2016 | 1,163 | 225 | N/A | 343 | N/A |
| 9/30/2016 | 1,122 | 228 | N/A | 244 | N/A |
| 6/30/2016 | 1,073 | 194 | N/A | 261 | N/A |
| 3/31/2016 | 1,030 | 175 | N/A | 233 | N/A |
| 12/31/2015 | 985 | 165 | N/A | 214 | N/A |
| 9/30/2015 | 948 | 161 | N/A | 204 | N/A |
| 6/30/2015 | 917 | 156 | N/A | 168 | N/A |
| 3/31/2015 | 892 | 154 | N/A | 151 | N/A |
| 12/31/2014 | 859 | 147 | N/A | 149 | N/A |
| 9/30/2014 | 831 | 149 | N/A | 137 | N/A |
| 6/30/2014 | 805 | 149 | N/A | 138 | N/A |
| 3/31/2014 | 773 | 138 | N/A | 108 | N/A |
| 12/31/2013 | 750 | 137 | N/A | 102 | N/A |
| 9/30/2013 | 718 | 119 | N/A | 91 | N/A |
| 6/30/2013 | 693 | 121 | N/A | 107 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 4004Das prognostizierte Gewinnwachstum (16% pro Jahr) liegt über der Sparquote (14.3%).
Ertrag vs. Markt: 4004Die Erträge des Unternehmens (16% pro Jahr) werden voraussichtlich schneller wachsen als der Markt SA (6.8% pro Jahr).
Hohe Wachstumserträge: 4004Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: 4004Die Einnahmen des Unternehmens (9.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt SA (-0.3% pro Jahr).
Hohe Wachstumseinnahmen: 4004Die Einnahmen des Unternehmens (9.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 4004Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (16.6 %).